"HPTX's MAMXIMUM revenue wll likely be only 30 million dollars since it WON'T be able to charge more than what already available drugs cost because ravicti so far can only claim NON-INFERIORITY..."
May 6, 2014, from the HPTX website:
"BRISBANE, Calif., May 6, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $19.5 million for the first quarter of 2014 from the sales of its two products for the treatment of urea cycle disorders, RAVICTI® (glycerol phenylbutyrate) Oral Liquid and BUPHENYL® (sodium phenylbutyrate) Tablets and Powder."
So that $30 million max revenue is now looking closer to $80 million and they're still adding new patients. For some added hilarity look up his posts from the board for OMER, a stock up 167% in the last 12 months. Oops!
rrtzrealmd (and his prediction about Hyperion's maximum revenue) is long gone from this board. And in the meantime, HPTX keeps generating increasing and impressive revenue through excellent uptake of Ravicti, and looks to do the same for a long time via a ridiculously long patent life and promising, potentially game-changing second indication. This should be a $40 stock at least.